... Astrocytoma IDH-mutant CNS WHO grade 3 Oligodendroglioma Oncolytic virotherapy Immunotherapy Radiology IDH-mutant astrocytomas are diffuse infiltrating astrocytic tumors lacking an identifiable border between the tumor and the healthy brain tissue. Transformation to glioblastoma multiforme (GBM...

..., and a complete response (CR) was maintained for 18 months. Conclusion: We report a rare case of a long-term response to pembrolizumab in ED-SCLC with TMB-high, highlighting the potential for targeted immunotherapy in such cases. [email protected] 26 11 2024 05 02 2025 06 03 2025 ©...

... Conjunctival melanoma Immune checkpoint inhibitors Immunotherapy LAG3 Melanoma Nivolumab Ocular tumors PD-1 Relatlimab SF3B1 Case report NIH Conjunctival melanoma is a rare, but deadly type of mucosal melanoma, accounting for less than 1% of all melanomas [ 1 ]. It has a high rate...

.... It also highlights how ECMO support enables the continuation of chemotherapy and the achievement of remission in CC. Furthermore, due to the inability to initiate the desired chemotherapy, immunotherapy was introduced as a possible treatment modality. Therefore, this case underscores the importance...

... progression. Conclusion: Typically, chest wall recurrence in TNBC has a poor prognosis; however, recurrence was rapidly controlled, sustained remission was achieved after immunotherapy combined with chemotherapy, and the curative effect continued after drug withdrawal, which is a rare occurrence. Thus...

... of follow-up, the patient experienced a local late recurrence in clinical stage rT4N0M0 requiring palliative chemotherapy (6 cycles of PF regimen). Due to progression, nivolumab-based immunotherapy was administered. After the 11th cycle of immunotherapy, high-dose re-irradiation (18 Gy in 3 fractions...

... for the programmed cell death ligand 1 protein (PD-L1). The response and survival of metastatic inflammatory TNBC to immunotherapy is largely unreported and we present a case of a young woman with metastatic triple negative inflammatory breast cancer, treated with pembrolizumab, carboplatin, and paclitaxel. Case...

... Vogt-Koyanagi-Harada disease Pembrolizumab Immunotherapy Immunotoxicity NIH Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by bilateral granulomatous uveitis and exudative retinal detachments in the absence of ocular trauma or surgery [ 1 ]. Neurologic...

... combination immunotherapy with ipilimumab plus nivolumab (Ipi/nivo) in a patient with T-NEPC who had failed standard treatment approaches. The patient was showing signs of a rapid decline in quality of life despite his prostate-specific antigen levels remaining undetectable and had no previous response...

... immunotherapy in a 66-year-old man with mRCC receiving a combination of ipilimumab and nivolumab in the first line of systemic therapy. GCA occurred 4 months after the initiation of IO and responded promptly to the low-dose prednisone therapy. Four months after the continuation of nivolumab maintenance...

...Xiufen Zheng; Jue Li; Zhenqing Gao; Yi Fang; Zikai Feng Introduction: Chemotherapy plus immunotherapy is the standard treatment worldwide for advanced lung squamous cell carcinoma with high programmed cell death protein-1 (PD-1) expression. The use of immunotherapy alone against advanced lung...

... therapy to the lesion and 6 months of combination immunotherapy with pembrolizumab and pharmacologic ascorbate, the mass measured 9 cm (middle). Six months later, it had continued to shrink, measuring under 8 cm (far right). b Two coronal images from three CT scans of a woman with soft tissue LMS...

... Presentation: We herein present the case of a woman with a nodal relapse of vaginal carcinoma, effectively treated with third-line immunotherapy. We will also provide a review of the literature on the new therapeutic strategies for advanced vaginal carcinoma, with a focus on pembrolizumab immunotherapy...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Immunotherapy Chimeric antigen receptor T cell Neurotoxicity Diffuse large B-cell lymphoma Case report...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Renal cell carcinoma Rheumatoid arthritis Immunotherapy Immune-related adverse events Pathological complete response Renal cell carcinoma (RCC) accounts...

... and there is only a small body of evidence for the use of immunotherapy in non-DEA eccrine carcinomas. We report the first case of metastatic DEA treated with a multimodality approach including surgery, radiotherapy, and immunotherapy, with an excellent prolonged response to pembrolizumab, and provide a review...

...Ian J. Robertson; Sierrah M. Grigsby; John C. Mattingly; Dean K. Park Bilateral synchronous renal cell carcinoma (RCC) is rare, especially in sporadic rather than familial cases. While immunotherapy has improved prognosis, RCC remains a diagnosis with significant morbidity and mortality...

... or advertisements. 2023 Abscopal effect Head and neck squamous cell carcinoma Immunotherapy Stereotactic body radiotherapy Radiotherapy (RT) has long been known to have an antitumour effect on distant lesions outside the primary irradiated area, a phenomenon that was described by Mole...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 Renal cell carcinoma Recurrence Immunotherapy Neoadjuvant therapy Renal cell carcinoma (RCC) accounts...

..., which may occur under benign or malignant conditions. This case presentation demonstrates the occurrence of AN in a patient following the diagnosis of urothelial carcinoma and ongoing treatment with PD-L1 inhibitor immunotherapy. Subsequent investigations ruled out a secondary malignancy or disease...